menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Miracogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"MRG001","moa":"\nBMPR2\/CXCR4\/CaN\/Cytokines\/FKBP1A","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Miracogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Miracogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Miracogen \/ Undisclosed"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DZD2269","moa":"A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"DB-1317","moa":"ADAM9","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AK131","moa":"Adenosine receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK131","moa":"Adenosine receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GT316","moa":"Amyloid-beta","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GT316","moa":"Amyloid-beta","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Hinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"HC1119","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hinova \/ Undisclosed"},{"orgOrder":0,"company":"Hinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hinova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hinova \/ Undisclosed"},{"orgOrder":0,"company":"Hinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hinova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hinova \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Peking University Cancer Hospital & Institute | Tianjin Medical University Cancer Institute and Hospital | Sun Yat-sen University | Ruijin Hospital | The First Affiliated Hospital with Nanjing Medical University | Hebei Medical University Fourth Hospital ","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Peking University Cancer Hospital & Institute | Tianjin Medical University Cancer Institute and Hospital | Sun Yat-sen University | Ruijin Hospital | The First Affiliated Hospital with Nanjing Medical University | Hebei Medical University Fourth Hospital ","highestDevelopmentStatusID":"6","companyTruncated":"Kintor Pharmaceutical \/ Peking University Cancer Hospital & Institute | Tianjin Medical University Cancer Institute and Hospital | Sun Yat-sen University | Ruijin Hospital | The First Affiliated Hospital with Nanjing Medical University | Hebei Medical University Fourth Hospital "},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SHR3680","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Androgen Receptor | Steroid 5-alpha-reductase | Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegylated Recombinant Human Endostatin","moa":"Angiogenesis","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Eoc Pharma","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eoc Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eoc Pharma \/ Immutep","highestDevelopmentStatusID":"6","companyTruncated":"Eoc Pharma \/ Immutep"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"SCB-313","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"SCB-313","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"SCB-313","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"SCB-313","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SCB-313","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Cancer Treatment International","sponsor":"ONCOtherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Pegarginase","moa":"Arginine","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Cancer Treatment International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Cancer Treatment International \/ ONCOtherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Cancer Treatment International \/ ONCOtherapeutics"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HX301","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HanX Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HanX Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATG-018","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATG-018","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AB-329","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHeart Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnHeart Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Sponsor GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Sponsor GmbH"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"14-C TGRX-326","moa":"Bacterial DNA gyrase","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Oncology","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aosaikang Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Pregene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BCMA CAR-NK Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pregene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Undisclosed"},{"orgOrder":0,"company":"Pregene","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"PRG1801","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0.16,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Pregene \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ICP-248","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ICP-248","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Apoptosis regulator Bcl-2 (BCL-2)||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pregene","sponsor":"Henan Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Henan Cancer Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Henan Cancer Hospital"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ IASO Bio"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ IASO Bio"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HLX60","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HLX60","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CT053PTSA","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CT053PTSA","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"HealthQuest Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"HQP1351","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ HealthQuest Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ HealthQuest Pharma"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"HealthQuest Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"14-C HQP1351","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ HealthQuest Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ HealthQuest Pharma"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"14-C TGRX-678","moa":"BCR-ABL|BCR-ABL T315I","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JAB-8263","moa":"BET","graph1":"Oncology","graph2":"Phase I","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Recombinant Human Endostatin","moa":"Beta-catenin (CTNNB1)","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Endostatin","moa":"Beta-catenin (CTNNB1)","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"QL1101","moa":"Bevacizumab biosimilar target (VEGF receptor)","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HSK42360","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fochon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"FCN-098","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Fochon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fochon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fochon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Icatolimab","moa":"||BTLA","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Binhui Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Oncolytic Type 2 Herpes Simplex Virus","moa":"Cancer cell","graph1":"Oncology","graph2":"Phase I","graph3":"Binhui Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Binhui Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Binhui Bio \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM369","moa":"CCR8","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM369","moa":"CCR8","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Connoya Biomedical Technology","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Connoya Biomedical Technology"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CM369","moa":"CCR8","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Connoya Biomedical Technology","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Connoya Biomedical Technology"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Zai Lab | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ZL-1218","moa":"CCR8","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Zai Lab | Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Zai Lab | Merck & Co"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"JS009","moa":"CD112R","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"JS006","moa":"||CD112R","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JS012","moa":"CD112R","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ ABL Bio"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sinotau Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"89-Zr CD147","moa":"CD147","graph1":"Oncology","graph2":"Phase I","graph3":"Sinotau Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinotau Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sinotau Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Anti-Cd19 Ucar-T","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"GC019F","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Series A Financing","leadProduct":"Inaticabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Juventas Cell Therapy","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Juventas Cell Therapy \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Juventas Cell Therapy \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"KJ-C2219","moa":"CD19\/CD20","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BR115","moa":"CD2\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioRay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HLX51","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"IBI301","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MIL62","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Mabworks Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Mabworks Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Coprelotamab","moa":"CD20\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"The First Affiliated Hospital with Nanjing Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"UB-VV400","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ The First Affiliated Hospital with Nanjing Medical University","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ The First Affiliated Hospital with Nanjing Medical University"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IMM47","moa":"CD24","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmuneOnco \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneOnco \/ IQVIA"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IBI3001","moa":"CD276\/EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"HS-20093","moa":"CD276\/Top I","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"HS-20093","moa":"CD276|Top I","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BR108","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioRay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TGI-6","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TG ImmunoPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TG ImmunoPharma \/ Undisclosed"},{"orgOrder":0,"company":"Binhui Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"BS006","moa":"CD3\/PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Binhui Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Binhui Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Binhui Bio \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Henan Cancer Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LBL-003","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Henan Cancer Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and Institute","highestDevelopmentStatusID":"6","companyTruncated":"Leads Biolabs \/ Henan Cancer Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and Institute"},{"orgOrder":0,"company":"Antengene","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATG-037","moa":"CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Merck & Co"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATG-037","moa":"CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"ATG-037","moa":"||CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GB268","moa":"CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyvgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LVGN7409","moa":"CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Lyvgen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyvgen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyvgen \/ Undisclosed"},{"orgOrder":0,"company":"Lyvgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LVGN7409","moa":"CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Lyvgen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyvgen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyvgen \/ Undisclosed"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"YH004","moa":"CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"YH004","moa":"CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AK132","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Fapon Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"FP002","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Fapon Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fapon Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fapon Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Fapon Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"FP002","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Fapon Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fapon Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fapon Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IMM01","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneOnco \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Letaplimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Shandong Cancer Hospital and Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"IMM2520","moa":"CD47\/PDL1","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Shandong Cancer Hospital and Institute","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneOnco \/ Shandong Cancer Hospital and Institute"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI322","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI322","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI322","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI322","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI322","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI322","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI322","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT125A","moa":"CD5","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"IB-T101","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMM40H","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneOnco \/ Undisclosed"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ABSK061","moa":"CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbisko Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abbisko Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biotheus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CD73 Antigen","moa":"CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotheus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biotheus \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI325","moa":"CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BC3195","moa":"CDH3\/P-cadherin","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCity Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BC3195","moa":"CDH3\/P-cadherin","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCity Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BC3195","moa":"CDH3\/P-cadherin","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCity Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"BC3195","moa":"||CDH3\/P-cadherin","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCity Biopharma \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Biopharma \/ Merck & Co"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dalpiciclib Isethionate","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SHR6390","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR6390","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR6390","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SHR6390","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GenFleet Therapeutics \/ Sellas Life Sciences Group","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Sellas Life Sciences Group"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"RAG-01","moa":"CDKN1A","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ractigen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RAG-01","moa":"CDKN1A","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ractigen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RAG-01","moa":"CDKN1A","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ractigen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RAG-01","moa":"CDKN1A","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BA1202","moa":"CEA","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Fortvita Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IBI3020","moa":"CEACAM5","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Fortvita Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Fortvita Biologics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IBI3020","moa":"CEACAM5","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Sinobioway Biomedicine Co. - Ltd","sponsor":"Jiangsu Cancer Institute & Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Tianjin Sinobioway Biomedicine Co. - Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Sinobioway Biomedicine Co. - Ltd \/ Jiangsu Cancer Institute & Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Sinobioway Biomedicine Co. - Ltd \/ Jiangsu Cancer Institute & Hospital"},{"orgOrder":0,"company":"Fochon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"FCN-011","moa":"c-Kit","graph1":"Oncology","graph2":"Phase I","graph3":"Fochon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fochon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fochon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HLX53","moa":"Claudin 18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Immunofoco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IMC002","moa":"Claudin 18.2 (CLDN18.2)","graph1":"Oncology","graph2":"Phase I","graph3":"Immunofoco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunofoco \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunofoco \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"RC118","moa":"Claudin-18 (CLDN18)","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"SKB315","moa":"Claudin-18 (CLDN18)","graph1":"Oncology","graph2":"Phase I","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AB011","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"AB011","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Shanghai East Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AB011","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Shanghai East Hospital","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Shanghai East Hospital"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AB011","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ATG-022","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Immunofoco","sponsor":"Changhai Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Claudin 18.2 CAR-T Cell","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Immunofoco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunofoco \/ Changhai Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Immunofoco \/ Changhai Hospital"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"CMG901","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"CMG901","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"CMG901","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DR30303","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Doer Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Doer Biologics \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Elevation Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Pharmaceutical Group","amount2":1.1799999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1799999999999999,"dosageForm":"Injection","sponsorNew":"CSPC Pharmaceutical Group \/ Elevation Oncology","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Pharmaceutical Group \/ Elevation Oncology"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI 360","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI 389","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Fortvita Biologics | Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Fortvita Biologics | Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Fortvita Biologics | Tigermed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IBI389","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Turning Point Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"LaNova Medicines","amount2":0.22,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.22,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Turning Point Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"LaNova Medicines \/ Turning Point Therapeutics"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ZL-1211","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Givastomig","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ ABL Bio"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Givastomig","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Givastomig","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Financing","leadProduct":"Givastomig","moa":"||CLDN18.2||OX40 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Everest Medicines","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Everest Medicines"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Financing","leadProduct":"Givastomig","moa":"||CLDN18.2||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Leerink Partners"},{"orgOrder":0,"company":"Fujian Cosunter Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GST-HG161","moa":"c-Met","graph1":"Oncology","graph2":"Phase I","graph3":"Fujian Cosunter Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Cosunter Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fujian Cosunter Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lyvgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LVGN6051","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I","graph3":"Lyvgen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyvgen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyvgen \/ Undisclosed"},{"orgOrder":0,"company":"Lyvgen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"LVGN6051","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I","graph3":"Lyvgen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyvgen \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Lyvgen \/ Merck & Co"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Donafenib","moa":"CRAF\/PDGFRs\/VEGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Donafenib","moa":"CRAF\/PDGFRs\/VEGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IMM27M","moa":"CTLA4","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneOnco \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneOnco \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMM27M","moa":"CTLA4","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneOnco \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneOnco \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Partnership","leadProduct":"CS1002","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"CStone Pharmaceuticals \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"CS1002","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CS1002","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"IBI310","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"FN-1501","moa":"Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fosun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fosun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fochon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"FCN-437","moa":"Cyclin-dependent kinase 4 (CDK4)","graph1":"Oncology","graph2":"Phase I","graph3":"Fochon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fochon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fochon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GLR2007","moa":"Cyclin-dependent kinase 4 (CDK4)","graph1":"Oncology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HSK46575","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase I","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"TYK Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I","graph3":"TYK Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TYK Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TYK Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fluconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SI-B003","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"YH001","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocytogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocytogen \/ Undisclosed"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"YH001","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"YH001","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Alphamab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Alphamab \/ Undisclosed"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alphamab Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alphamab Oncology \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ICP-033","moa":"DDR1\/DDR2\/PDGFR?\/PDGFR?\/VEGFR2\/VEGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IBI3009","moa":"DLL3","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"IBI3009","moa":"DLL3","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":1.0800000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.0800000000000001,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8009","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8009","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APG-5918","moa":"EED","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APG-5918","moa":"EED","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APG-5918","moa":"EED","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Sanhome Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SH-1028","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Nanjing Sanhome Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanjing Sanhome Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanjing Sanhome Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Sanhome Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SH1573","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Nanjing Sanhome Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nanjing Sanhome Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanjing Sanhome Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Sanhome Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SHC014748M","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Nanjing Sanhome Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanjing Sanhome Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanjing Sanhome Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SCT200","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SCT200","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"14-C D-0316","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BAT4306F","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"InventisBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"D-0316","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InventisBio \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HSK40118","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Larotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"307 Hospital of PLA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Anti-EGFR Antibody","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Kelun Pharmaceutical \/ 307 Hospital of PLA","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Kelun Pharmaceutical \/ 307 Hospital of PLA"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Selatinib Ditosilate","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"TQB6411","moa":"EGFR | c-Met","graph1":"Oncology","graph2":"Phase I","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gumarontinib","moa":"EGFR exon 20 insertion mutant","graph1":"Oncology","graph2":"Phase I","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gumarontinib","moa":"EGFR exon 20 insertion mutant","graph1":"Oncology","graph2":"Phase I","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ABSK112","moa":"EGFR exon 20\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbisko Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abbisko Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BPI-15086","moa":"EGFR T790M","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Covance | XuanZhu Pharma Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"KBP-5209","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase I","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sihuan Pharmaceutical \/ Covance | XuanZhu Pharma Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Sihuan Pharmaceutical \/ Covance | XuanZhu Pharma Co., Ltd."},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BL-B16D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BL-B16D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BL-B16D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IBI3005","moa":"EGFR\/HER3\/Top 1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Lepu Biopharma","sponsor":"Lepu Medical Technology | West China Hospital | Jiyan Liu","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"MRG003","moa":"EGFR|Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Lepu Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lepu Biopharma \/ Lepu Medical Technology | West China Hospital | Jiyan Liu","highestDevelopmentStatusID":"6","companyTruncated":"Lepu Biopharma \/ Lepu Medical Technology | West China Hospital | Jiyan Liu"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SHR2554","moa":"Enhancer of zeste homolog 2 (EZH2)","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SHR2554","moa":"Enhancer of zeste homolog 2 (EZH2)","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"SHR2554","moa":"Enhancer of zeste homolog 2 (EZH2)","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SHR2554","moa":"Enhancer of zeste homolog 2 (EZH2)","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SHR2554","moa":"Enhancer of zeste homolog 2 (EZH2)","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tucidinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tucidinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"Ionova Life Science","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INV-1120","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ionova Life Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionova Life Science \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Ionova Life Science \/ Merck & Co"},{"orgOrder":0,"company":"Ionova Life Science","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"INV-1120","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ionova Life Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionova Life Science \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Ionova Life Science \/ Merck & Co"},{"orgOrder":0,"company":"Ionova Life Science","sponsor":"Tsing Song Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"INV-1120","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ionova Life Science","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ionova Life Science \/ Tsing Song Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ionova Life Science \/ Tsing Song Capital"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palupiprant","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adlai Nortye \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Adlai Nortye \/ Merck & Co"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cipatinib","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SI-B001","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Synermore Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"SYN004","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I","graph3":"Synermore Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synermore Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synermore Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pyrotinib","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Disitamab Vedotin","moa":"ERBB2","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HF158K1","moa":"ErbB2","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HF158K1","moa":"ErbB2","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan YZY Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"M802","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Wuhan YZY Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wuhan YZY Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Wuhan YZY Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Bliss Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"BB-1701","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Bliss Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bliss Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bliss Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bliss Bio","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"BB-1701","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Bliss Bio","amount2":2,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Infusion","sponsorNew":"Bliss Bio \/ Eisai","highestDevelopmentStatusID":"6","companyTruncated":"Bliss Bio \/ Eisai"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DZD1516","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"GQ1001","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneQuantum Healthcare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneQuantum Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"China Life Private Equity Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Series C Financing","leadProduct":"GQ1001","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneQuantum Healthcare \/ China Life Private Equity Investment","highestDevelopmentStatusID":"6","companyTruncated":"GeneQuantum Healthcare \/ China Life Private Equity Investment"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"MBS301","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Mabworks Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATG-017","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Antengene","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATG-017","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ AstraZeneca"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATG-017","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATG-017","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Pegol-Sihematide","moa":"Erythropoietin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"14-C GB491","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"JS InnoPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JSI-1187","moa":"Extracellular signal-regulated kinase 1 (ERK1)","graph1":"Oncology","graph2":"Phase I","graph3":"JS InnoPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"JS InnoPharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JS InnoPharm \/ Undisclosed"},{"orgOrder":0,"company":"JS InnoPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JSI-1187","moa":"Extracellular signal-regulated kinase 1 (ERK1)","graph1":"Oncology","graph2":"Phase I","graph3":"JS InnoPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"JS InnoPharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JS InnoPharm \/ Undisclosed"},{"orgOrder":0,"company":"JS InnoPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dabrafenib","moa":"||Extracellular signal-regulated kinase 1 (ERK1)","graph1":"Oncology","graph2":"Phase I","graph3":"JS InnoPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"JS InnoPharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JS InnoPharm \/ Undisclosed"},{"orgOrder":0,"company":"JS InnoPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JSI-1187","moa":"Extracellular signal-regulated kinase 1 (ERK1)","graph1":"Oncology","graph2":"Phase I","graph3":"JS InnoPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"JS InnoPharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JS InnoPharm \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"14-C SHR2554","moa":"EZH2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"APG-2449","moa":"FAK\/ALK\/ROS1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APG-2449","moa":"FAK\/ALK\/ROS1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"APG-2449","moa":"FAK\/ALK\/ROS1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Signet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SIGX1094R","moa":"FAK\/SRC","graph1":"Oncology","graph2":"Phase I","graph3":"Signet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Signet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Signet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"3D185","moa":"FGFR","graph1":"Oncology","graph2":"Phase I","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CS3006","moa":"FGFR1\/FGFR2\/FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CS3006","moa":"FGFR1\/FGFR2\/FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"SIM0686","moa":"FGFR2 | FGFR2b | Top I","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"HDM2020","moa":"FGFR2b","graph1":"Oncology","graph2":"Phase I","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ABSK-011","moa":"FGFR4","graph1":"Oncology","graph2":"Phase I","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abbisko Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ICP-105","moa":"FGFR4","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"Fibroblast growth factor receptor 3 | Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"XY0206","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Tigermed"},{"orgOrder":0,"company":"Polymed Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HPB-092","moa":"FLT3 | IRAK4","graph1":"Oncology","graph2":"Phase I","graph3":"Polymed Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Polymed Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Polymed Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InxMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Undisclosed"},{"orgOrder":0,"company":"InxMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Undisclosed"},{"orgOrder":0,"company":"InxMed","sponsor":"Hyfinity Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"Ifebemtinib","moa":"||Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Inhalation","sponsorNew":"InxMed \/ Hyfinity Investments","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Hyfinity Investments"},{"orgOrder":0,"company":"InxMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"InxMed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Undisclosed"},{"orgOrder":0,"company":"InxMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"InxMed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Undisclosed"},{"orgOrder":0,"company":"InxMed","sponsor":"Ennovation Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"Ifebemtinib","moa":"||Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Ennovation Ventures","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Ennovation Ventures"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"CAR-GPC3 T Cell","moa":"Glypican-3 (GPC3)","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Nanjing PLA 81 Hospital | First Affiliated Hospital of Zhejiang University | RenJi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CAR-GPC3 T Cell","moa":"Glypican-3 (GPC3)","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Nanjing PLA 81 Hospital | First Affiliated Hospital of Zhejiang University | RenJi Hospital","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Nanjing PLA 81 Hospital | First Affiliated Hospital of Zhejiang University | RenJi Hospital"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Shanghai Zhongshan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CAR-GPC3 T Cell","moa":"Glypican-3 (GPC3)","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Shanghai Zhongshan Hospital","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Shanghai Zhongshan Hospital"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Ruijin Hospital, Shanghai Jiao Tong University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CAR-GPRC5D T Cell","moa":"GPRC5D","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Ruijin Hospital, Shanghai Jiao Tong University","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ Ruijin Hospital, Shanghai Jiao Tong University"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Xianxiang Medical Technology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SIM0500","moa":"GPRC5D\/BCMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Licensing Agreement","leadProduct":"SIM0500","moa":"GPRC5D\/BCMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":1.0600000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.0600000000000001,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ AbbVie Inc"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Mirati Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HDM2005","moa":"HDM allergens","graph1":"Oncology","graph2":"Phase I","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HDM2005","moa":"HDM allergens","graph1":"Oncology","graph2":"Phase I","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Hepalink Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"H1710","moa":"Heparanase","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Hepalink Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Hepalink Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Hepalink Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BPI-9016M","moa":"Hepatocyte growth factor receptor | Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BPI-9016M","moa":"Hepatocyte growth factor receptor | Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Bao Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"KJ015","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Bao Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Bao Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Bao Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BAT1006","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BAT8001","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BAT8003","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BL-M17D1","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BL-M17D1","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"GQ1005","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneQuantum Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HLX22","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"HLX22","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"RC48-ADC","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"RC48-ADC","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SSGJ-612","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"IBI315","moa":"HER2\/PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"KM257","moa":"HER2D4","graph1":"Oncology","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"AK138D1","moa":"HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AK138D1","moa":"HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BPI-452080","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Shanghai De Novo Pharmatech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"DN1406131","moa":"IDO1\/TDO","graph1":"Oncology","graph2":"Phase I","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qingfeng Pharmaceutical Group \/ Shanghai De Novo Pharmatech Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Qingfeng Pharmaceutical Group \/ Shanghai De Novo Pharmatech Co., Ltd."},{"orgOrder":0,"company":"Shanghai Allink Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ALK202","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Allink Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Allink Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Allink Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"9MW3811","moa":"IL-11 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"9MW3811","moa":"IL-11 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BAT6021","moa":"IL-17A","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BAT6021","moa":"IL-17A","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Genakumab","moa":"IL-17A","graph1":"Oncology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"AWT020","moa":"IL-2R\/PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AK114","moa":"IL-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BAT6005","moa":"IL-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HLX23","moa":"IL-4R?","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"LP-001","moa":"K-ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longbio Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Longbio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS387","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-421286","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HBI-2438","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IBI351","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IBI351","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JMKX001899","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jemincare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JMKX001899","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jemincare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"JMKX001899","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jemincare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HRS-6093","moa":"KRAS protein","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"IBI397","moa":"LAG-3","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LBL-007","moa":"LAG3 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI110","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"IBI110","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IBI110","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IBI110","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI110","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI323","moa":"LAG3\/PDL1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ZGGS15","moa":"LAG3\/TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI188","moa":"Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI188","moa":"Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"IBI188","moa":"Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"IBI188","moa":"Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI188","moa":"Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ZL-1201","moa":"Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ES009","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ES009","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0.13,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ABSK021","moa":"Macrophage colony-stimulating factor 1 receptor (CSF1R)","graph1":"Oncology","graph2":"Phase I","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abbisko Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABSK021","moa":"Macrophage colony-stimulating factor 1 receptor (CSF1R)","graph1":"Oncology","graph2":"Phase I","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abbisko Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"Cellular tumor antigen p53 (TP53)||MDM2-p53","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"Cellular tumor antigen p53 (TP53)||MDM2-p53","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABM-168","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABM-168","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABM-168","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"HTI-1066","moa":"MET","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AB-218","moa":"mIDH1","graph1":"Oncology","graph2":"Phase I","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnHeart Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"ERK activator kinase (MEK)||Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"ERK activator kinase (MEK)||Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"ERK activator kinase (MEK)||Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"IBI101","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Lemzoparlimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":1.9399999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.9399999999999999,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"TJ011133","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Merck & Co"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"HDM2012","moa":"MUC17 | Top I","graph1":"Oncology","graph2":"Phase I","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Zhejiang Tumor Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BAT8007","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Zhejiang Tumor Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Zhejiang Tumor Hospital"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BAT8007","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Bulumtatug Fuvodotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BRY805","moa":"NKG2A","graph1":"Oncology","graph2":"Phase I","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioRay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HY-0102","moa":"NKG2A","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"TCRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KSX01-TCRT","moa":"NY-ESO-1","graph1":"Oncology","graph2":"Phase I","graph3":"TCRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TCRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TCRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BAT6026","moa":"OX40 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BAT6026","moa":"OX40 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BAT1308","moa":"||OX40 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Biocytogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YH001","moa":"||OX40L receptor (CD134)","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eucure Biopharma \/ Biocytogen","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Biocytogen"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Syncromune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"YH002","moa":"OX40L receptor (CD134)","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eucure Biopharma \/ Syncromune","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Syncromune"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"YH002","moa":"OX40L receptor (CD134)","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"YH002","moa":"OX40L receptor (CD134)","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATG-019","moa":"PAK4","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATG-019","moa":"||PAK4","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AN2025","moa":"Pan-PI3K","graph1":"Oncology","graph2":"Phase I","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adlai Nortye \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adlai Nortye \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HRS-1167","moa":"PARP1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HRS-1167","moa":"PARP1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"HRS-1167","moa":"PARP1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":1.48,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.48,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Merck Group"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fuzuloparib","moa":"PARP1 \/ PARP2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"14-C Fluzoparib","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"14-C IMP4297","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Baiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BY101921","moa":"PARP-7","graph1":"Oncology","graph2":"Phase I","graph3":"Chengdu Baiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu Baiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Baiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BAT1308","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CS3002","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI319","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI319","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI319","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI321","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI321","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI321","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI321","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Fortvita Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IBI363","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Fortvita Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Fortvita Biologics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IBI363","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IBI363","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IBI363","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"JS007","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"CMAB Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JS201","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ CMAB Biopharma Inc","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ CMAB Biopharma Inc"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JS201","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY01008","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MW11","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Toripalimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Sponsor GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Sponsor GmbH"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Toripalimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Toripalimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Toripalimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK129","moa":"PD-1\/LAG-3","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK129","moa":"PD-1\/LAG-3","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BAT7104","moa":"PD-1\/PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Sun Yat-sen University","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BAT7104","moa":"PD-1\/PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ George Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ George Clinical"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BAT7104","moa":"PD-1\/PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CS2009","moa":"PD-1\/VEGF\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CS2009","moa":"PD-1\/VEGF\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CS2009","moa":"PD-1\/VEGF\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fapon Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"FP-008","moa":"PD-1|IL-10M","graph1":"Oncology","graph2":"Phase I","graph3":"Fapon Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fapon Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fapon Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Chasesun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IMMH-010","moa":"PDL1","graph1":"Oncology","graph2":"Phase I","graph3":"Tianjin Chasesun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Chasesun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Chasesun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-371153","moa":"PDL1","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AN4005","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adlai Nortye \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adlai Nortye \/ Undisclosed"},{"orgOrder":0,"company":"Xiamen Biotime Biotechnology","sponsor":"Adlai Nortye","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"AN4005","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Xiamen Biotime Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Biotime Biotechnology \/ Adlai Nortye","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Biotime Biotechnology \/ Adlai Nortye"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ASC61","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ASC61","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ASC61","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BAT4706","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BAT4706","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CS3005","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GB222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GB222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"HLX20","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAE005","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Qure Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Q-1802","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Qure Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qure Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qure Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SHR-1316","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR-1316","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TJ-L14B","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ ABL Bio"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HLX35","moa":"PD-L1\/CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HLX35","moa":"PD-L1\/CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ADG206","moa":"PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Xianxiang Medical Technology Co., Ltd. | Simcere Zaiming","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SIM0237","moa":"PD-L1\/IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd. | Simcere Zaiming","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd. | Simcere Zaiming"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Xianxiang Medical Technology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"SIM0237","moa":"PD-L1\/IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SIM0237","moa":"PD-L1\/IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-aHPPH","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Linperlisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Linperlisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Linperlisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-21668","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CYH33","moa":"PI3K?","graph1":"Oncology","graph2":"Phase I","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CYH33","moa":"PI3K?","graph1":"Oncology","graph2":"Phase I","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"IMP4297","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"IMP4297","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"IMP4297","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IMP4297","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IMP4297","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMP4297","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMP4297","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Senaparib","moa":"||Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"307 Hospital of PLA | Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fluzoparib","moa":"poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ 307 Hospital of PLA | Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ 307 Hospital of PLA | Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fluzoparib","moa":"poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"The Third Xiangya Hospital of Central South University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fluzoparib","moa":"poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ The Third Xiangya Hospital of Central South University","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ The Third Xiangya Hospital of Central South University"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Hunan Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fluzoparib","moa":"poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Hunan Cancer Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Hunan Cancer Hospital"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fluzoparib","moa":"poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ The Affiliated Hospital of the Chinese Academy of Military Medical Sciences"},{"orgOrder":0,"company":"Suzhou Puhe Biopharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"BAY 3713372","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I","graph3":"Suzhou Puhe Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Puhe Biopharma \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Suzhou Puhe Biopharma \/ Bayer AG"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HSK41959","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"IBI318","moa":"Programmed cell death 1 ligand 1 (PD-L1)","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI318","moa":"Programmed cell death 1 ligand 1 (PD-L1)","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI318","moa":"Programmed cell death 1 ligand 1 (PD-L1)","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MSB2311","moa":"Programmed cell death 1 ligand 1 (PD-L1)","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"MSB2311","moa":"Programmed cell death 1 ligand 1 (PD-L1)","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MSB2311","moa":"Programmed cell death 1 ligand 1 (PD-L1)","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SCT-I10A","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"SCT-I10A","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"AK-105","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"CS1003","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"CS1003","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GB226","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genor Biopharma \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Genor Biopharma \/ Hutchmed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Geptanolimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Geptanolimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genor Biopharma \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Genor Biopharma \/ Hutchmed"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"GLS-010","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"SHR-1210","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"SHR-1210","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"SHR-1210","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SHR-1210","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"609A","moa":"Programmed cell death protein 1 (PD-1)","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"609A","moa":"Programmed cell death protein 1 (PD-1)","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"LZM009","moa":"Programmed cell death protein 1 (PD-1)","graph1":"Oncology","graph2":"Phase I","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Bright Peak Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"LZM009","moa":"Programmed cell death protein 1 (PD-1)","graph1":"Oncology","graph2":"Phase I","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Livzon Pharmaceutical Group \/ Bright Peak Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Livzon Pharmaceutical Group \/ Bright Peak Therapeutics"},{"orgOrder":0,"company":"Synermore Biologics","sponsor":"Synermore Biologics USA Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SYN125","moa":"Programmed cell death protein 1 (PD-1)","graph1":"Oncology","graph2":"Phase I","graph3":"Synermore Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synermore Biologics \/ Synermore Biologics USA Limited","highestDevelopmentStatusID":"6","companyTruncated":"Synermore Biologics \/ Synermore Biologics USA Limited"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"AK-104","moa":"Programmed cell death protein 1 | Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MGD013","moa":"Programmed cell death protein 1 | Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AN0025","moa":"Prostaglandin E2 receptor EP4 (PTGER4)","graph1":"Oncology","graph2":"Phase I","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adlai Nortye \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Adlai Nortye \/ Merck & Co"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AN0025","moa":"Prostaglandin E2 receptor EP4 (PTGER4)","graph1":"Oncology","graph2":"Phase I","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adlai Nortye \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adlai Nortye \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CS231295","moa":"Protein kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CS231295","moa":"Protein kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Prosperity7 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Prosperity7 Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Prosperity7 Ventures"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"SKB518","moa":"PTK7","graph1":"Oncology","graph2":"Phase I","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Medicine Co Ltd","sponsor":"Ambrx Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"ARX788","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang Medicine Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Medicine Co Ltd \/ Ambrx Inc","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Medicine Co Ltd \/ Ambrx Inc"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Termination","leadProduct":"AV-203","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase I","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Aveo Oncology","highestDevelopmentStatusID":"6","companyTruncated":"CANbridge Pharmaceuticals \/ Aveo Oncology"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BR111","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioRay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"CS5001","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"CS5001","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"CS5001","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zion Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"ZN-A-1041","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Zion Pharma","amount2":0.68000000000000005,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Capsule, Enteric Coated","sponsorNew":"Zion Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Zion Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Zion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ZN-A-1041","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Zion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zion Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DS6051b","moa":"ROS1 \/ NTRK","graph1":"Oncology","graph2":"Phase I","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnHeart Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chiauranib","moa":"Serine\/threonine-protein kinase Aurora-B | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ABM-1310","moa":"Serine\/threonine-protein kinase B-raf (BRAF)","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABM-1310","moa":"Serine\/threonine-protein kinase B-raf (BRAF)","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ABM-1310","moa":"Serine\/threonine-protein kinase B-raf (BRAF)","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ABM-1310","moa":"Serine\/threonine-protein kinase B-raf (BRAF)","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABM-1310","moa":"Serine\/threonine-protein kinase B-raf (BRAF)","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABM-1310","moa":"Serine\/threonine-protein kinase B-raf (BRAF)","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABM-1310","moa":"Serine\/threonine-protein kinase B-raf (BRAF)","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LianBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ Undisclosed"},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ AstraZeneca"},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ AstraZeneca"},{"orgOrder":0,"company":"LianBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LianBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-442096","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BR790","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HBI-2376","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HS-10381","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Arrivent","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Arrivent"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ICP-189","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ICP-189","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin ConjuStar Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SC-102","moa":"Stress-activated protein kinase 2a (p38 alpha)","graph1":"Oncology","graph2":"Phase I","graph3":"Tianjin ConjuStar Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin ConjuStar Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin ConjuStar Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI939","moa":"T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI939","moa":"T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI939","moa":"T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI939","moa":"T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GC027","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GC027","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BPI-460372","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TST005","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"TST005","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TST005","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TST005","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sinopharm Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Series B Financing","leadProduct":"GFH018","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Sinopharm Capital","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Sinopharm Capital"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HLX26","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HLX26","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JS006","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"JS006","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.28999999999999998,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK130","moa":"TIGIT\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK130","moa":"TIGIT\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||TNF2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SIM1811-03","moa":"TNFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SIM1811-03","moa":"TNFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Simmitecan","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LNK01002","moa":"Triple kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"LNK01002","moa":"Triple kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Lynk Pharmaceuticals \/ Lilly Asia Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharmaceuticals \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-28592","moa":"TrkA","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HLX42","moa":"TROP2","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BL-M08D1","moa":"Trop-2","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BL-M08D1","moa":"Trop-2","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CSPC Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Shanghai 10th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GC201 TIL","moa":"Tumor antigens","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GC203 TIL","moa":"Tumor antigens","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Juncell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Third Affiliated Hospital of Naval Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GC203 TIL","moa":"Tumor antigens","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Juncell Therapeutics \/ Third Affiliated Hospital of Naval Medical University","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Third Affiliated Hospital of Naval Medical University"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GC203 TIL","moa":"Tumor antigens","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Juncell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ANS03","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TYK Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TYK-00540","moa":"TYK2","graph1":"Oncology","graph2":"Phase I","graph3":"TYK Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TYK Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TYK Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ANS014004","moa":"Type-2 c-met tyrosine kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Shanghai Chest Hospital | Hunan Cancer Hospital | Henan Cancer Hospital | Zhejiang Cancer Hospital | Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ANS014004","moa":"Type-2 c-met tyrosine kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Shanghai Chest Hospital | Hunan Cancer Hospital | Henan Cancer Hospital | Zhejiang Cancer Hospital | Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Shanghai Chest Hospital | Hunan Cancer Hospital | Henan Cancer Hospital | Zhejiang Cancer Hospital | Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ANS014004","moa":"Type-2 c-met tyrosine kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TT-01488","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TransThera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TransThera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TT-01488","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TransThera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TransThera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Biomissile Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BM230","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biomissile Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomissile Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biomissile Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing RegeneCore Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"RJK-RT2831","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nanjing RegeneCore Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanjing RegeneCore Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanjing RegeneCore Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Sanhome Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SH3051","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nanjing Sanhome Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nanjing Sanhome Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanjing Sanhome Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Sanhome Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SH3765","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nanjing Sanhome Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanjing Sanhome Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanjing Sanhome Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Sanhome Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SH3809","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nanjing Sanhome Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanjing Sanhome Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanjing Sanhome Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qingdao Sino-Cell Biomedicine","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences | The First Hospital of Jilin University | West China Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HS-IT101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qingdao Sino-Cell Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingdao Sino-Cell Biomedicine \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences | The First Hospital of Jilin University | West China Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Qingdao Sino-Cell Biomedicine \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences | The First Hospital of Jilin University | West China Hospital"},{"orgOrder":0,"company":"Qingdao Sino-Cell Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-IT101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qingdao Sino-Cell Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingdao Sino-Cell Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qingdao Sino-Cell Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Qingdao Sino-Cell Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-IT101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qingdao Sino-Cell Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingdao Sino-Cell Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qingdao Sino-Cell Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Qingdao Sino-Cell Biomedicine","sponsor":"The Affiliated Hospital of Qingdao University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HS-IT201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qingdao Sino-Cell Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingdao Sino-Cell Biomedicine \/ The Affiliated Hospital of Qingdao University","highestDevelopmentStatusID":"6","companyTruncated":"Qingdao Sino-Cell Biomedicine \/ The Affiliated Hospital of Qingdao University"},{"orgOrder":0,"company":"Shanghai Best-Link Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BL0006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Best-Link Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Best-Link Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Best-Link Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Best-Link Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BL0020","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Best-Link Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Best-Link Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Best-Link Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Best-Link Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BL0175","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Best-Link Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Best-Link Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Best-Link Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai De Novo Pharmatech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"DN1508052-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai De Novo Pharmatech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai De Novo Pharmatech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai De Novo Pharmatech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Escugen Biotechnology","sponsor":"Escugen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ESG206","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Escugen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Escugen Biotechnology \/ Escugen","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Escugen Biotechnology \/ Escugen"},{"orgOrder":0,"company":"Shanghai Escugen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ESG206","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Escugen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Escugen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Escugen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Escugen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ESG406","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Escugen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Escugen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Escugen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"F0002-ADC","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"FDA018-ADC","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"FDA022","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FZ-AD004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FZ-AD005","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai GeneChem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Meso-Cart Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai GeneChem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai GeneChem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai GeneChem \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kanda Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KD6001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Kanda Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Kanda Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Kanda Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai OriginCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai OriginCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai OriginCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai OriginCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai OriginCell Therapeutics","sponsor":"Shanghai General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocytes","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai OriginCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai OriginCell Therapeutics \/ Shanghai General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai OriginCell Therapeutics \/ Shanghai General Hospital"},{"orgOrder":0,"company":"Shanghai Pushi Medical Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FS-8002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Pushi Medical Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Pushi Medical Science \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Pushi Medical Science \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen NewDEL Biotech","sponsor":"Shenzhen Innovation Center for Small Molecule Drug Discovery | Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ND-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen NewDEL Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen NewDEL Biotech \/ Shenzhen Innovation Center for Small Molecule Drug Discovery | Sun Yat-sen University","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen NewDEL Biotech \/ Shenzhen Innovation Center for Small Molecule Drug Discovery | Sun Yat-sen University"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Recombinant Full Human Anti-Egfr Monoclonal Antibody","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SCTB35","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SCTC21C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ZG0895 HCl","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TCRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KSH01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TCRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TCRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TCRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TCRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KSH01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TCRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TCRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TCRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin ConjuStar Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SC-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tianjin ConjuStar Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tianjin ConjuStar Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin ConjuStar Biologics \/ Undisclosed"},{"orgOrder":0,"company":"TYK Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TY-2136b","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TYK Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TYK Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TYK Medicines \/ Undisclosed"},{"orgOrder":0,"company":"TYK Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TY-2699a","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TYK Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TYK Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TYK Medicines \/ Undisclosed"},{"orgOrder":0,"company":"TYK Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TY-302","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TYK Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TYK Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TYK Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan YZY Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Y101D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Wuhan YZY Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wuhan YZY Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Wuhan YZY Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan YZY Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Y150","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Wuhan YZY Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wuhan YZY Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Wuhan YZY Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"1A46","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioRay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioRay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"304","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"3D011-08","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"3D189","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"9MW3011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"9MW3011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Tianweiyuanhe Biomedical","sponsor":"3E Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Series A Financing","leadProduct":"A-319","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tianweiyuanhe Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tianweiyuanhe Biomedical \/ 3E Bioventures","highestDevelopmentStatusID":"6","companyTruncated":"Tianweiyuanhe Biomedical \/ 3E Bioventures"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ABSK043","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abbisko Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ABSK121-NX","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbisko Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abbisko Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AK117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AK-1286","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AK137","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AK146D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AK146D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Fudan University Shanghai Cancer Center ( FUSCC )","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AK154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Fudan University Shanghai Cancer Center ( FUSCC )","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Fudan University Shanghai Cancer Center ( FUSCC )"},{"orgOrder":0,"company":"Kind Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AND019","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kind Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kind Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kind Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"APL-1501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Asieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Asieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ASKC202","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aosaikang Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Fudan University","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Fudan University"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"B001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"B002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"B003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BA1106","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BA1301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BA1302","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bliss Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BB-1705","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bliss Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bliss Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bliss Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bliss Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BB-1709","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bliss Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bliss Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bliss Bio \/ Undisclosed"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BC3402","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioCity Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BC3402","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCity Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BG1805","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guangzhou Bio-gene Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou Bio-gene Technology \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Beihai Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CAS 139306-10-8","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zhuhai Beihai Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhuhai Beihai Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhuhai Beihai Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Beihai Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BH009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zhuhai Beihai Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhuhai Beihai Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhuhai Beihai Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Bio-008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"BJ Bioscience","sponsor":"PPD | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BJ-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BJ Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BJ Bioscience \/ PPD | Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"BJ Bioscience \/ PPD | Merck & Co"},{"orgOrder":0,"company":"BJ Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"BJ-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BJ Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BJ Bioscience \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"BJ Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"BJ Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BJ-005","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BJ Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BJ Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BJ Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BL-M02D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BL-M02D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BL-M05D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BL-M09D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BL-M09D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BL-M11D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BL-M14D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"InnoBM Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BM201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"InnoBM Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"InnoBM Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoBM Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BPI-16350","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BR101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioRay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BR105","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioRay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BRY812","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioRay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BRY812","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioRay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"ImmVira","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"C5252","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmVira \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ Undisclosed"},{"orgOrder":0,"company":"ImmVira","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"C5252","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmVira \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ Undisclosed"},{"orgOrder":0,"company":"ImmVira","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"C5252","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmVira \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Cafusertib HCl","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Cafusertib HCl","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CytoCares","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CC312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CytoCares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CytoCares \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CytoCares \/ Undisclosed"},{"orgOrder":0,"company":"CD (Suzhou) Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CD-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CD (Suzhou) Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CD (Suzhou) Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CD (Suzhou) Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"CD (Suzhou) Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CD-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CD (Suzhou) Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CD (Suzhou) Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CD (Suzhou) Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CN1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Curon Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Curon Biopharmaceutical \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Curon Biopharmaceutical \/ Novotech"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CS23546","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CT011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CT0596","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CTA101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioheng Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CTA101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioheng Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CTB001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioheng Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Undisclosed"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"D3L-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"D3 Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"D3 Bio \/ Undisclosed"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"D3S-002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"D3 Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"D3 Bio \/ Undisclosed"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"DB-1312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":1.3,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"DB-1312","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":1.3,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"DB-1312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":1.3,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DR30206","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Doer Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Doer Biologics \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"EG017","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"EMB-07","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpimAb Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EpimAb Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"EMB-09","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpimAb Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EpimAb Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eoc Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"EOC317","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eoc Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eoc Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eoc Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ES002023","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ES101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ES102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ES102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elpiscience \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"F182112","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"F527","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fochon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FCN-338","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fochon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fochon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fochon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"FS-1502","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fosun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Gamma-Delta T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guangzhou Bio-gene Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou Bio-gene Technology \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GC007g","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"GC007g","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GC101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Juncell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GenEros BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GEC255","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GenEros BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenEros BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GenEros BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GenSci122","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GenSci128","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Ruijin Hospital | Shanghai Tong Ren Hospital | First Affiliated Hospital of Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Gentulizumab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Ruijin Hospital | Shanghai Tong Ren Hospital | First Affiliated Hospital of Zhejiang University","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Ruijin Hospital | Shanghai Tong Ren Hospital | First Affiliated Hospital of Zhejiang University"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Gentulizumab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Gentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Shanghai East Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Gentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Shanghai East Hospital","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Shanghai East Hospital"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GNC-035","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GNC-035","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GNC-035","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GNC-039","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GNC-077","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GNC-077","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GNC-077","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GT101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"CICC Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Series B Financing","leadProduct":"GT101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ CICC Capital","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ CICC Capital"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GT201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GT201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GTE001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HBT-708","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HEC68498","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HEC89736","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HF1K16","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"HighField Biopharmaceuticals \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Tigermed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HF1K16","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HF50","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HF50","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HF50","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HitGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Hg146","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HitGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HitGen \/ Undisclosed"},{"orgOrder":0,"company":"HitGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Hg146","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HitGen \/ Undisclosed"},{"orgOrder":0,"company":"HitGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HG381","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"HitGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HitGen \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HH30134","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HR19024","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HRS2300","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HRS2543","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HRS-3738","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HRS-6209","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HRS-7053","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HRS-7172","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HRS7415","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HRS8807","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HRS-9815","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"HS-10241","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HS-10241","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"HS-10241","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"HS-10342","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HS-10352","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HS-10352","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HS-10370","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HS-20089","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HS-20089","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HS-20090","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-20108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-20110","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Biotheus","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"HS-20117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biotheus \/ Hansoh Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Biotheus \/ Hansoh Pharma"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HS-20117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-20122","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-20124","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HS269","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSK29116","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HX009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HanX Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HanX Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"IBI345","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ICP-B794","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ICP-B794","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"IMP7068","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMPACT Therapeutics, Inc \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Covance"},{"orgOrder":0,"company":"JenKem Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"JK-1201I","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"JenKem Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JenKem Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JenKem Technology \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Zhejiang Hangyu Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"JMKX000197","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jemincare \/ Zhejiang Hangyu Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Zhejiang Hangyu Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Jemincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JMKX000197","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jemincare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Zhejiang Hangyu Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JMKX003948","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jemincare \/ Zhejiang Hangyu Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Zhejiang Hangyu Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JS107","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JS107","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"JS108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JS207","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Sponsor GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Sponsor GmbH"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JSKN016","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Alphamab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Alphamab \/ Undisclosed"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"JWATM214","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JW Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JW Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JYB1907","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jemincare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Undisclosed"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KM501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KM602","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KN052","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Alphamab \/ Undisclosed"},{"orgOrder":0,"company":"Kunming Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"KY100001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kunming Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kunming Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kunming Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"L&L Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LB4330","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"L&L Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"L&L Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"L&L Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Likang Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"LK101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Likang Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Likang Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Likang Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Likang Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"LK101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Likang Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Likang Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Likang Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LNF1901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Sun Yat-sen University","highestDevelopmentStatusID":"6","companyTruncated":"Lunan Pharmaceutical \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LNF2007","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Nanjing Bangnuo Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"LPM3480226","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luye Pharma \/ Nanjing Bangnuo Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Nanjing Bangnuo Biotechnology"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LPM6690176","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"LX-039","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"LXI-15029","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"FutureGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"M108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"FutureGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FutureGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"FutureGen \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Shanghai 10th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Membrane Bound Cytokine Modified TIL","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Metatinib Tromethamine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Metatinib Tromethamine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MH048","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MHB118C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MIL93","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Mabworks Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MIL95","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Mabworks Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MIL97","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Mabworks Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Mabworks Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MSB0254","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NCR300","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nuwacell Biotechnologies \/ The First Affiliated Hospital of University of Science and Technology of China","highestDevelopmentStatusID":"6","companyTruncated":"Nuwacell Biotechnologies \/ The First Affiliated Hospital of University of Science and Technology of China"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NCR300","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Beijing Friendship Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Nuwacell Biotechnologies \/ Beijing Friendship Hospital"},{"orgOrder":0,"company":"NK CellTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NK042","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NK CellTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NK CellTech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NK CellTech \/ Undisclosed"},{"orgOrder":0,"company":"Base Therapeutics","sponsor":"The General Hospital of Eastern Theater Command","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NK510","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Base Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Base Therapeutics \/ The General Hospital of Eastern Theater Command","highestDevelopmentStatusID":"6","companyTruncated":"Base Therapeutics \/ The General Hospital of Eastern Theater Command"},{"orgOrder":0,"company":"Base Therapeutics","sponsor":"Shanghai 10th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NK510","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Base Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Base Therapeutics \/ Shanghai 10th People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Base Therapeutics \/ Shanghai 10th People's Hospital"},{"orgOrder":0,"company":"Base Therapeutics","sponsor":"Shanghai General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NK510","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Base Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Base Therapeutics \/ Shanghai General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Base Therapeutics \/ Shanghai General Hospital"},{"orgOrder":0,"company":"Base Therapeutics","sponsor":"Shanghai Children's Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NK520","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Base Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Base Therapeutics \/ Shanghai Children's Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Base Therapeutics \/ Shanghai Children's Medical Center"},{"orgOrder":0,"company":"Base Therapeutics","sponsor":"Shanghai Pudong Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NK520","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Base Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Base Therapeutics \/ Shanghai Pudong Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Base Therapeutics \/ Shanghai Pudong Hospital"},{"orgOrder":0,"company":"NanoMab Technology","sponsor":"University Hospital Aachen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"NM-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NanoMab Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoMab Technology \/ University Hospital Aachen","highestDevelopmentStatusID":"6","companyTruncated":"NanoMab Technology \/ University Hospital Aachen"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NM1F","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TG ImmunoPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TG ImmunoPharma \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NWY001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NWY001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"OriCAR-017","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OriCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biotheus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PM1009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biotheus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biotheus \/ Undisclosed"},{"orgOrder":0,"company":"Biotheus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PM1021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotheus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biotheus \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"QL1706","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"QL1706","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QL1706H","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QL2107","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"QL2109","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"QLC1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QLF3108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"QLF32004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QLF32101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QLH11811","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QLH11906","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLM2011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QLS1103","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QLS12004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLS1209","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLS1304","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"QLS31901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QLS31903","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QLS31904","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"QLS4131","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLS5132","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"RC108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RC148","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RC198","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"RC98","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Tianweiyuanhe Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Anti-EpCAM\/CD3 Bispecific Antibody","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tianweiyuanhe Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tianweiyuanhe Biomedical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianweiyuanhe Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Cancer Treatment International","sponsor":"University of Hong Kong","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Recombinant Human Arginase 1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Cancer Treatment International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Cancer Treatment International \/ University of Hong Kong","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Cancer Treatment International \/ University of Hong Kong"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Recombinant Humanized anti-PD-1 Monoclonal Antibody","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SC10914","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCR-6920","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SHR -1316","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SHR-1501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SHR-1501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SHR-1702","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SHR-1702","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR-1909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR-1916","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-2005","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR4394","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"SHR-4849","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":1.05,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.05,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Ideaya Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Ideaya Biosciences"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR7280","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-7367","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SHR7390","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SHR7390","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SHR9146","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SHR9549","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SHR-A1403","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SHR-A1811","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR-A1904","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR-A1904","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-A1904","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SIM0348","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Xianxiang Medical Technology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SIM0501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Xianxiang Medical Technology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SIM0505","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"NextCure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"SIM0505","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0.75,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.75,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ NextCure","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ NextCure"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Xianxiang Medical Technology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SIM0508","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Shanghai Xianxiang Medical Technology Co., Ltd."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SIM1803-1A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Simmitecan HCl","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences","highestDevelopmentStatusID":"6","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Simotinib HCl","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SKB535","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SPGL008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SPH 3348","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SPH1188-11","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SPH5030","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SPH5030","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SPH6516","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SPH7485","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Palm Beach CRO | Keystone Bioanalytical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SQ001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Livzon Pharmaceutical Group \/ Palm Beach CRO | Keystone Bioanalytical","highestDevelopmentStatusID":"6","companyTruncated":"Livzon Pharmaceutical Group \/ Palm Beach CRO | Keystone Bioanalytical"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SSGJ-705","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SSGJ-706","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Macquarie University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SSGJ-709","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Macquarie University","highestDevelopmentStatusID":"6","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Macquarie University"},{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SSS59","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SW1115C3","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stemirna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Stemirna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SW1115C3","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stemirna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Stemirna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CellOrigin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"SY001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CellOrigin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellOrigin Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CellOrigin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SYH2043","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SYHX2005","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"TopAlliance Biosciences, Inc. | CTI Clinical Trial and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TAB006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences, Inc. | CTI Clinical Trial and Consulting","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences, Inc. | CTI Clinical Trial and Consulting"},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"GenScript Biotech Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"TAEST16001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xiangxue Life Sciences \/ GenScript Biotech Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue Life Sciences \/ GenScript Biotech Corporation"},{"orgOrder":0,"company":"TCRCure Biopharma","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"TC-N201 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TCRCure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCRCure Biopharma \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"6","companyTruncated":"TCRCure Biopharma \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sir Run Run Shaw Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TGRX-1942","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ Sir Run Run Shaw Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ Sir Run Run Shaw Hospital"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TJ210001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TJ210001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TJ210001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQB2825","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TSN084","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tyligand Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tyligand Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TSN084","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tyligand Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tyligand Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TT-00434","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransThera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TransThera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TT-00973-MS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TransThera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TransThera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Shanghai 10th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Shanghai 10th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte Therapy","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Juncell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Second Affiliated Hospital, Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocytes","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Juncell Therapeutics \/ Second Affiliated Hospital, Soochow University","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Second Affiliated Hospital, Soochow University"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Shanghai 10th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocytes","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Shanghai Tong Ren Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocytes","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Juncell Therapeutics \/ Shanghai Tong Ren Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Shanghai Tong Ren Hospital"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Sir Run Run Shaw Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocytes","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Juncell Therapeutics \/ Sir Run Run Shaw Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Sir Run Run Shaw Hospital"},{"orgOrder":0,"company":"Shanghai Juncell Therapeutics","sponsor":"Shanghai 10th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocytes","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Juncell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Juncell Therapeutics \/ Shanghai 10th People's Hospital"},{"orgOrder":0,"company":"Zhejiang Haichang Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"WGI-0301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang Haichang Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Haichang Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Haichang Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"WJ47156","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Sponsor GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Sponsor GmbH"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"XNW7201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evopoint Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evopoint Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Fudan University | Shanghai General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"XZ120","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Fudan University | Shanghai General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Lunan Pharmaceutical \/ Fudan University | Shanghai General Hospital"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XZB-0004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XZB-0004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"XZP-5809-TT1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Excyte Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"YK012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Excyte Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Excyte Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Excyte Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Excyte Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"YKST02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Excyte Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Excyte Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Excyte Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"YL-17231","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"YL-17231","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"YL211","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MediLink Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"MediLink Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Collaboration","leadProduct":"YL211","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MediLink Therapeutics","amount2":1,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Infusion","sponsorNew":"MediLink Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"MediLink Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"YL217","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MediLink Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MediLink Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"YS-0N-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Z650","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ZL-1310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zai Lab \/ Zai Lab","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Zai Lab"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ZL-1310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ZL-1310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ZX-4081","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HS-10382","moa":"Unknown","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HS-10382","moa":"Unknown","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS-10386","moa":"Unknown","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS-10502","moa":"Unknown","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-10502","moa":"Unknown","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HS-10504","moa":"Unknown","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-10529","moa":"Unknown","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan Humanwell Hi-tech Industry Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HW071021","moa":"Unknown","graph1":"Oncology","graph2":"Phase I","graph3":"Wuhan Humanwell Hi-tech Industry Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Wuhan Humanwell Hi-tech Industry Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Wuhan Humanwell Hi-tech Industry Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"HLX04","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lucitanib","moa":"Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences","highestDevelopmentStatusID":"6","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"apatinib mesylate","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"apatinib mesylate","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"apatinib mesylate","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"apatinib mesylate","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"apatinib mesylate","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Henatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Famitinib","moa":"Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor 3 | Vascular endothelial growth factor receptor 1 | Stem cell growth factor receptor | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Sun Yat-sen University","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Famitinib","moa":"Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor 3 | Vascular endothelial growth factor receptor 1 | Stem cell growth factor receptor | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Sevacizumab","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Sevacizumab","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Sevacizumab","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Eoc Pharma","sponsor":"Fountain Medical Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Telatinib Mesylate","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eoc Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eoc Pharma \/ Fountain Medical Development","highestDevelopmentStatusID":"6","companyTruncated":"Eoc Pharma \/ Fountain Medical Development"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||VEGFA","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"AL3810","moa":"VEGFR\/PDGFR\/FGFR","graph1":"Oncology","graph2":"Phase I","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences","highestDevelopmentStatusID":"6","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GB223","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Chinese Academy of Medical Sciences | Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Famitinib Malate","moa":"VEGFR2 \/ PDGFR \/ c-Kit","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Chinese Academy of Medical Sciences | Chinese Academy of Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Chinese Academy of Medical Sciences | Chinese Academy of Sciences"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Famitinib Malate","moa":"VEGFR2 \/ PDGFR \/ c-Kit","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Famitinib Malate","moa":"VEGFR2 \/ PDGFR \/ c-Kit","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xiangxue Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical"},{"orgOrder":0,"company":"iCamuno","sponsor":"I Peace","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"iCamuno","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iCamuno \/ I Peace","highestDevelopmentStatusID":"6","companyTruncated":"iCamuno \/ I Peace"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Sinorda Biomedicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanyou Biopharmaceuticals \/ Sinorda Biomedicine","highestDevelopmentStatusID":"6","companyTruncated":"Sanyou Biopharmaceuticals \/ Sinorda Biomedicine"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HSK42360","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Base Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NK510","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Base Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Base Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Base Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"QLS2309","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HRS-2329","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BAFFR CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guangzhou Bio-gene Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou Bio-gene Technology \/ Undisclosed"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCMA\/GPRC5D CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guangzhou Bio-gene Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou Bio-gene Technology \/ Undisclosed"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Junson Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2025","type":"Financing","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Full-Life Technologies \/ Junson Capital","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Junson Capital"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Zhengzhou Yihe Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GT801","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Zhengzhou Yihe Hospital","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Zhengzhou Yihe Hospital"},{"orgOrder":0,"company":"Jemincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"JMKX005425","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jemincare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Undisclosed"}]

    Find Oncology Drugs in Phase I Clinical Development in CHINA

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GRIT Biotechnology

                            China arrow
                            OTS 2025
                            Not Confirmed

                            GRIT Biotechnology

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GT801

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Zhengzhou Yihe Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refract...

                            Details : GT801 is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Hematologic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 03, 2025

                            Lead Product(s) : GT801

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Zhengzhou Yihe Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bio-Thera Solutions

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Bio-Thera Solutions

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants

                            Details : Pembrolizumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 18, 2025

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hangzhou Zhongmei Huadong Pharmaceutical

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Hangzhou Zhongmei Huadong Pharmaceutical

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HDM2012

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of HDM2012 in Patients with Advanced Solid Tumor

                            Details : HDM2012 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            August 03, 2025

                            Lead Product(s) : HDM2012

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lepu Biopharma

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Lepu Biopharma

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MRG003

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Lepu Medical Technology | West China Hospital | Jiyan Liu

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MRG003 + HX008 Tested In EGFR+ Advanced Penile Squamous Cell Carcinoma

                            Details : MRG003 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Penile Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            July 08, 2025

                            Lead Product(s) : MRG003

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Lepu Medical Technology | West China Hospital | Jiyan Liu

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shenzhen TargetRx

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 14-C TGRX-678

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The First Affiliated Hospital of Soochow University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGRX-678 Pharmacokinetic Mass Balance

                            Details : 14-C TGRX-678 is a Radiolabelled Compounds drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 23, 2025

                            Lead Product(s) : 14-C TGRX-678

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The First Affiliated Hospital of Soochow University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Zai Lab

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Zai Lab

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZL-1310,Atezolizumab,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zai Lab Gets FDA Fast Track for DLL3 ADC ZL-1310 in Small Cell Lung Cancer

                            Details : ZL-1310 is the Company’s potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate (ADC), being investigated for the treatment of extensive-stage small cell lung cancer (ES-SCLC).

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 19, 2025

                            Lead Product(s) : ZL-1310,Atezolizumab,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Hansoh Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-10370

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

                            Details : HS-10370 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 09, 2025

                            Lead Product(s) : HS-10370

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Hansoh Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-20108

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Study of HS-20108 in Participants With Advanced Solid Tumors

                            Details : HS-20108 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 20, 2025

                            Lead Product(s) : HS-20108

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Genor Biopharma

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Genor Biopharma

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GB268

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors

                            Details : GB268 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 18, 2025

                            Lead Product(s) : GB268

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Hansoh Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-20110

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of HS-20110 in Participants With Advanced Solid Tumors

                            Details : HS-20110 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 24, 2025

                            Lead Product(s) : HS-20110

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth